StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.03−0.03 (-2.83%)

Close on Nov 18, 2026Market cap $103.35MP/E –Yield –

Cellectis revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was $72.95M, up 75.8% from the year before. Over ten years it grew 2.7% a year on average. The highest annual figure on record is $72.95M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$72.95M+75.8%
FY2024Dec 31, 2024$41.51M+5397.4%
FY2023Dec 31, 2023$755.00K-96.1%
FY2022Dec 31, 2022$19.17M-36.8%
FY2021Dec 31, 2021$30.35M-40.6%
FY2020Dec 31, 2020$51.06M+236.1%
FY2019Dec 31, 2019$15.19M+19.3%
FY2018Dec 31, 2018$12.73M-49.5%
FY2017Dec 31, 2017$25.19M-43.8%
FY2016Dec 31, 2016$44.81M-19.8%
FY2015Dec 31, 2015$55.86M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.23M+300.1%
Q2 FY2025Jun 30, 2025$16.73M+49.7%
Q2 FY2024Jun 30, 2024$8.06M+178.0%
Q2 FY2023Jun 30, 2023$178.00K-84.5%
Q2 FY2022Jun 30, 2022$1.31M–
Q2 FY2021Jun 30, 2021$11.18M–
Q2 FY2020Jun 30, 2020$2.90M–
Q2 FY2019Jun 30, 2019$1.15M–

More Cellectis figures

See a number that looks wrong?